SL
GILD icon

Sentinus LLC’s Gilead Sciences GILD Stock Holding History

Sentinus LLC’s Portfolio GILD Stock Details GILD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$282K Buy
2,233
+105
+5% +$13.8K 0.02% 497
2026
Q1 		$297K Buy
+2,128
New +$298K 0.03% 425

Other funds holding GILD

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Sentinus LLC's GILD Position: Q2 2026 in Review

Sentinus LLC increased its Gilead Sciences (GILD) stake by 4.9% in Q2 2026, buying an estimated $13.8K and bringing the position to 2,233 shares worth $282K. The position accounts for 0.02% of the portfolio, ranked #497.

Sentinus LLC first reported a position in GILD in Q1 2026 and has held it in 2 quarters since. The position peaked at $297K in Q1 2026. 2,271 funds tracked by Wall St. Rank hold GILD as of Q2 2026.

  • Sentinus LLC held 2,233 shares of Gilead Sciences worth $282K as of Q2 2026.
  • Sentinus LLC bought 105 Gilead Sciences shares in Q2 2026, an estimated $13.8K.
  • Gilead Sciences made up 0.02% of Sentinus LLC's portfolio in Q2 2026, its #497 holding.
  • Sentinus LLC first reported a position in Gilead Sciences in Q1 2026 and has held it in 2 quarters since.
  • Sentinus LLC's Gilead Sciences position peaked at $297K in Q1 2026.
  • 2,271 funds tracked by Wall St. Rank held Gilead Sciences as of Q2 2026.

Based on Sentinus LLC's 13F filing for Q2 2026, filed 11 Aug 2026.